SUMMARY R-loops comprise an RNA/DNA hybrid and displaced single-stranded DNA. They play important biological roles and are implicated in pathology. Even so, proteins recognizing these structures are largely undefined. Using affinity purification with the S9.6 antibody coupled to mass spectrometry, we defined the RNA/DNA hybrid interactome in HeLa cells. This consists of known R-loop-associated factors SRSF1, FACT, and Top1, and yet uncharacterized interactors, including helicases, RNA processing, DNA repair, and chromatin factors. We validate specific examples of these interactors and characterize their involvement in R-loop biology. A top candidate DHX9 helicase promotes R-loop suppression and transcriptional termination. DHX9 interacts with PARP1, and both proteins prevent R-loop-associated DNA damage. DHX9 and other interactome helicases are overexpressed in cancer, linking R-loop-mediated DNA damage and disease. Our RNA/DNA hybrid interactome provides a powerful resource to study R-loop biology in health and disease.
INTRODUCTION
R-loops consist of an RNA/DNA hybrid and a displaced nontemplate DNA strand. These structures are thermodynamically stable and can arise during transcription, where they contribute to gene regulation at multiple levels (Ginno et al., 2012; SkourtiStathaki et al., 2011; Yang et al., 2014) . They also are involved in immunoglobulin class switch recombination, DNA replication, and regulation of DNA and histone modifications (Aguilera and García-Muse, 2012; Skourti-Stathaki and Proudfoot, 2014) .
Despite crucial biological processes associated with R-loops, many aspects of R-loop biology remain unclear. Which factors influence R-loop formation at different genomic locations? How are R-loop levels precisely controlled to allow for their beneficial functions while preventing detrimental effects from dysregulated R-loops? Failure to correctly control R-loop levels results in increased DNA damage and genome instability (Aguilera and García-Muse, 2012; Skourti-Stathaki and Proudfoot, 2014; Sollier and Cimprich, 2015) and aberrant transcriptional termination (Skourti-Stathaki et al., 2011 . Recent studies have implicated R-loops in the pathology of human diseases (Groh and Gromak, 2014) . R-loops can form at expanded trinucleotide DNA repeats, leading to heterochromatin formation and transcriptional repression of genes associated with neurological disorders, including amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD), Friedreich ataxia, and fragile X syndrome (Colak et al., 2014; Groh et al., 2014; Haeusler et al., 2014) . A growing body of evidence also connects R-loops to processes that are deregulated in cancer, including DNA repair, replication, and gene expression of tumor-promoting genes (Bhatia et al., 2014; Boque-Sastre et al., 2015; Hatchi et al., 2015; Kotsantis et al., 2016; Schwab et al., 2015; Stork et al., 2016; Yang et al., 2014) .
Genetic screens have been used to identify factors that regulate R-loop levels in yeast (Chan et al., 2014; Stirling et al., 2012; Wahba et al., 2011) . However, these screens could not distinguish direct or indirect effects of these factors on R-loops, and the molecular mechanisms linking these factors to R-loop biology are still not understood fully. Human cells possess dedicated enzymes that can directly bind and regulate R-loop levels, including members of the RNase H family that specifically degrade the RNA in R-loops (Cerritelli and Crouch, 2009 ) and the helicase senataxin (SETX) that can unwind RNA/DNA hybrids (Skourti-Stathaki et al., 2011) . It is interesting that mutations in RNase H and SETX lead to devastating neurological disorders, further underlining the importance of maintaining the correct R-loop balance in human cells (Groh et al., 2017; Groh and Gromak, 2014) . Considering the complexity of RNA-processing reactions and the high abundance of non-coding RNA transcription, R-loop formation is a likely consequence that will require the availability of protein factors to directly control R-loop levels.
We used an unbiased approach to purify RNA/DNA hybrids and identify their associated proteins by mass spectrometry (MS) in human cells. This RNA/DNA hybrid interactome comprises 469 proteins, including helicases, RNA/DNA-binding proteins, and factors implicated in DNA damage. More important, we identify and validate factors previously implicated in R-loop biology, including SRSF1 and Top1, as well as candidate RNA/DNA hybrid interactors DHX9, PARP1, SAFB2, WHSC1, and DNA-PK. We demonstrate that a top candidate DHX9 helicase prevents R-loop accumulation in vivo and is required for transcriptional termination. We also describe a role of DHX9 in maintaining genome stability. DHX9 interacts with PARP1, and the loss of these proteins leads to R-loop accumulation, which triggers DNA damage. DHX9 and other RNA/DNA hybrid-interacting helicases are overexpressed in cancers, highlighting their potential role in the cancer transcriptional program. In conclusion, our data show that the RNA/DNA hybrid interactome reveals new RNA/DNA hybrid-interacting proteins and provides a link between fundamental aspects of R-loop biology and human disease. 
RESULTS

Design and Validation of the RNA/ DNA Hybrid IP Method
To identify RNA/DNA hybrid-interacting factors in an unbiased way, we developed an affinity purification approach, using the S9.6 antibody, which specifically recognizes RNA/DNA hybrids with 0.6 nM affinity (Boguslawski et al., 1986; Phillips et al., 2013) . Nuclear extracts were prepared from HeLa cells and sonicated before immunoprecipitation (IP) to minimize copurification of unspecific proteins (Figures 1A and S1A) . Non-crosslinked cells were used because crosslinking reagents could induce R-loops (Schwab et al., 2015) , preventing the identification of bona fide R-loop interactors. IP using the S9.6 antibody was carried out in the presence of RNase A to reduce unspecific RNA-mediated interactions and avoid S9.6 recognition of double-stranded RNA (dsRNA) ( Figure S1B ). RNase A treatment before IP did not affect RNA/DNA hybrid IP results, suggesting that R-loops are not formed artificially during the extraction procedure (data not shown). We verified that the RNA/DNA hybrid IP enriches for RNA/DNA hybrids using the RNA/DNA hybrid slot blot, which quantitatively detects both endogenous and synthetic RNA/DNA hybrids (Figures 1B and S1C) . Silver staining of immunoprecipitated RNA/DNA hybrid-interacting proteins revealed a complex mixture of proteins, which differed from the nuclear input material ( Figure 1C ) or IP carried out with antibody-recognizing cap-binding protein 80 (CBP80) ( Figure S1D ). More important, little protein was detected in no antibody or matched isotype immunoglobulin G2 (IgG2) negative IP controls. These results suggest that the RNA/DNA hybrid IP enriches a unique set of interacting proteins.
To test possible cross-reactivity of the S9.6 antibody with proteins, nuclear extracts were treated with benzonase, which degrades all forms of nucleic acids, including RNA/DNA hybrids, without affecting proteins ( Figure S1E ). Benzonase caused a loss of immunoprecipitated proteins ( Figure 1D ), confirming that RNA/DNA hybrid IP proteins are associated with nucleic acids recognized by the S9.6 antibody.
Next, we validated our IP procedure by testing copurification of proteins already implicated in R-loop biology. In particular, we detected the RNA/DNA helicase SETX, which resolves R-loops at termination regions ( Figure 1C , bottom) (Hatchi et al., 2015; Skourti-Stathaki et al., 2011) and Top1 (El Hage et al., 2010; Tuduri et al., 2009 ). In line with cotranscriptional R-loop formation, RNA polymerase II (Pol II) also was detected.
As an integral part of chromatin, RNA/DNA hybrids interacted with histone H3 but not with actin.
To verify that proteins identified in the RNA/DNA hybrid IP specifically bind RNA/DNA hybrids, we added synthetic 15-23 bp competitors during the IP procedure. When 15-bp RNA/DNA hybrid with 0.54 nM affinity for S9.6 antibody (Phillips et al., 2013) was added, a significant competition was observed for most concentrations, as demonstrated by a loss of copurified proteins, including Top1 and H3 (Figures 1E and 1F and S1F) . In contrast, the addition of corresponding dsDNA, dsRNA, and 23 bp AU-rich dsRNA, which has low affinity for S9.6 in vitro (Phillips et al., 2013) , did not affect RNA/DNA hybrid IP efficiency . Supporting the specificity of our method, we did not detect the loss of proteins in the CBP80 IP in the presence of each competitor ( Figure S1D ).
In conclusion, even though a low affinity of S9.6 antibody with dsRNA in mild buffer conditions has been reported (Phillips et al., 2013) , our stringent purification procedure and the use of RNase A ensures that the RNA/DNA hybrid IP method exhibits high specificity and efficiently enriches for proteins associated with RNA/DNA hybrids.
Characterization of the RNA/DNA Hybrid Interactome We then developed a proteomic pipeline based on label-free quantitative MS to identify proteins associated with RNA/DNA hybrids in HeLa cells. To achieve the highest specificity, we compared protein enrichment in RNA/DNA hybrid IP to a control IP with S9.6 antibody in the presence of 1.3 mM RNA/DNA hybrid competitor. In total, 846 proteins were identified with high reproducibility (r > 0.77) in three biological replicates using MaxQuant software ( Figure S2A ) (Cox and Mann, 2008) . Next, by using a moderated t test, we identified 469 candidate factors significantly enriched in the RNA/DNA hybrid versus control IP (Smyth, 2004) . These proteins represent the RNA/DNA hybrid interactome (Figure 2A , orange data points). Analysis of our MS data with an independent approach based on the normalized spectral index (SIN) (Trudgian et al., 2011) found a strong correlation between the two methods (r = 0.796), confirming the robustness of the analysis (Figures S2B and S2C) . We subdivided the RNA/ DNA hybrid interactome into three classes according to their statistical significance: class I (top 25%), class II (next 50%), and class III (bottom 25%) ( Figure S2D) . A representative list of identified proteins, encompassing a variety of cellular functions, is provided in Table S2 .
As expected, the RNA/DNA hybrid interactome almost exclusively contained nuclear proteins ( Figure S2E ). However, we observed no correlation between their cellular abundance (Geiger et al., 2012) and enrichment in the RNA/DNA hybrid interactome ( Figure S2F ), indicating that the RNA/DNA hybrid IP enriches for a specific subset of the proteome. Indeed, protein classes involved in RNA metabolism, such as heterogeneous nuclear ribonucleoproteins (hnRNPs), SR proteins and splicing factors, DNA-binding proteins (including Top1 and FACT), and chromatin-associated proteins, were overrepresented (Figure 2B) . Notably, we detected many helicases acting on RNA (DDX5 and DHX9) or DNA (MCM3) and a high enrichment of RNA/DNA-binding domains, including RNA recognition motif (RRM); K homology (KH); double-stranded RNA-binding domains (dsRBDs); and SAF-A/B, acinus, and PIAS (SAP) (Figure S2G) . This suggests that the RNA/DNA hybrid IP detects direct interactions rather than secondary interactions mediated by protein-protein binding.
We also investigated whether the RNA/DNA hybrid interactome exhibits additional characteristics. Comparison of the RNA/DNA hybrid interactome to the HeLa mRNA interactome (Castello et al., 2012) showed that despite an overlap between the two datasets, a significant part of the RNA/DNA hybrid interactome (187 proteins) is unique ( Figure 2C , top). While proteins common to both interactomes are enriched for RNA-related functions, factors unique to the RNA/DNA hybrid interactome are involved in DNA and chromatin biology ( Figure 2C , bottom). See also Figure S2 .
Consequently, we also detected an overall enrichment for proteins with high chromatin probability ( Figure 2D ) (Kustatscher et al., 2014) and proteins capable of binding to both RNA and DNA ( Figure 2E ) (Hudson and Ortlund, 2014) compared to the HeLa proteome. More important, there was no correlation between protein abundance in the RNA/DNA hybrid interactome and chromatin probability, demonstrating that our method enriches for a specific subset of proteins over the chromatin background ( Figure S2H ). It is interesting that the RNA/DNA hybrid interactome also was enriched for factors mediating genome stability (Paulsen et al., 2009) (Figure S2J ), whereas other abundant protein classes were depleted ( Figure S2I Figure 2F ). In particular, we confirmed a number of proteins already implicated in R-loop biology, including the 5 0 -3 0 exonuclease XRN2, previously associated with R-loop-mediated transcription termination (SkourtiStathaki et al., 2011) and SRSF1 (Li and Manley, 2005; Tuduri et al., 2009 ). In addition, we validated candidates with previously unreported function in R-loop metabolism in vivo, including DHX9, DDX5, WHSC1, SAFB2, DNA-PK, and PARP1. We also confirmed the absence of abundant nuclear proteins, including Drosha, Lamin B1, and nuclear pore complex (NPC).
To confirm the specificity of these RNA/DNA hybrid interactors, we performed a modified version of the RNA/DNA hybrid IP with RNase H treatment ( Figure 3A ). The genomic DNA was extracted from HeLa cells and enriched for RNA/DNA hybrids with the S9.6 antibody. These genomic RNA/DNA hybrids were then incubated with HeLa nuclear extracts, depleted for RNA/ DNA hybrids by treatment with a high concentration of RNase A, followed by IP of RNA/DNA-binding proteins with the S9.6 antibody (Figures 3B and 3C and S3A) . All new R-loop-interacting candidates, including Top1, used as a positive control, can bind genomic RNA/DNA hybrids ( Figure 3C ). In contrast, treatment of the genomic DNA with RNase H strongly decreased the amount of copurified proteins, which correlated with the decrease in the RNA/DNA hybrid signal on the slot blot ( Figures  3B and 3C ).
To further investigate the involvement of selected candidates in R-loop biology, we performed slot blot analyses upon small interfering RNA (siRNA)-mediated depletion of these candidates ( Figures S3C-3H ). We observed that the knockdown of DHX9, WHSC1, SAFB2, and DNA-PK decreases the global level of RNA/DNA hybrids ( Figures 3E-3H and S3B ), whereas depletion of PARP1 and Top1 triggers an increase ( Figures 3D and 3I) . Moreover, the S9.6 signal was abolished by RNase H treatment, indicating that it is specific to RNA/DNA hybrids ( Figures 3D-3I) . Even though the mechanistic basis of the global R-loop changes requires further investigation, these results demonstrate that the RNA/DNA hybrid interactome uncovers new factors involved in R-loop biology.
DHX9 Promotes Transcriptional Termination
We detected several helicases enriched in the RNA/DNA interactome, suggesting that this protein class may play yet uncharacterized roles in R-loop biology. Therefore, we decided to further investigate the R-loop-associated function of a top validated candidate, DHX9. DHX9 has been shown to possess RNA/ DNA helicase activity in vitro (Chakraborty and Grosse, 2011) . To establish whether DHX9 associates with RNA/DNA hybrids in vivo, we confirmed the specificity of this interaction biochemically. RNA/DNA hybrid IP carried out with benzonase or RNase H treatments significantly reduced DHX9-RNA/DNA hybrid interaction ( Figures S4A and 3C ). Cell treatment with the transcriptional inhibitor actinomycin D also dramatically reduced DHX9-RNA/DNA hybrid interaction, suggesting that this interaction is transcription dependent (Figures 4A and 4B) . Furthermore, DXH9-RNA/DNA hybrid interaction was prevented by synthetic RNA/DNA hybrid competitor but not by corresponding dsDNA, dsRNA, and AU-rich dsRNA competitors ( Figure S4B ). RNA/ DNA hybrids also co-immunoprecipitated (coIP) with DHX9 but not with tubulin or no antibody control IPs ( Figures 4C and 4D) . These experiments confirm that DHX9 interacts with RNA/DNA hybrids in vivo.
We further examined the R-loop-associated biological functions of DHX9 in vivo. In line with its potential function in R-loop biology, endogenous DHX9 is predominantly localized throughout the nucleus ( Figure 4E ), and it is enriched at promoter-proximal regions of b-actin and g-actin genes, as demonstrated by chromatin immunoprecipitation (ChIP) ( Figures S4C  and S4D ). Therefore, we examined the R-loop profile of the b-actin and g-actin genes in DHX9-depleted cells, using DNA/ RNA immunoprecipitation (DIP) (Skourti-Stathaki et al., 2011) . As a positive control, we also depleted SETX, which resolves R-loops at the termination regions of the b-actin gene (SkourtiStathaki et al., 2011) . R-loops are enriched over the promoterproximal and termination regions of the b-actin (in1, pause, and 5 0 pause) (Skourti-Stathaki et al., 2011) and g-actin (in1, A) genes ( Figures 4G and 4H ). R-loops were increased over the termination regions of both genes in DHX9-and SETX-depleted cells , and the DIP signal was sensitive to RNase H treatment ( Figure S5E ). These data suggested that similar to SETX, DXH9 promotes R-loop suppression at termination regions.
Next, we investigated whether the function of DHX9 in R-loop metabolism in poly(A)-proximal regions of b-actin and g-actin genes can affect their transcriptional termination, as previously shown for SETX (Skourti-Stathaki et al., 2011) . Similar to SETX, DHX9 depletion caused an increase in the amount of readthrough transcripts downstream of the poly(A) signal ( Figure 4I ) and stabilization of Pol II over the transcription termination region for both genes ( Figure S4G ). These data pointed toward a role for DHX9 in R-loop suppression during transcriptional termination.
DHX9 Depletion Triggers R-Loop Accumulation in
Response to CPT Defects in transcription termination resulting from SETX or XRN2 depletion have been associated with R-loop accumulation and R-loop-driven genome instability (Hatchi et al., 2015; Morales et al., 2016) . Because DHX9-depleted cells exhibit a termination defect ( Figures 4H and 4I ), we examined the potential role of DHX9 in preventing R-loop-associated DNA damage. For these studies, we used the Top1 inhibitor camptothecin (CPT), which is known to promote R-loop accumulation and replication-and transcription-associated DNA damage caused by unresolved DNA supercoiling (Marinello et al., 2016; Sordet et al., 2009 ). CPT treatment induced DNA damage, as indicated by the phosphorylation of histone variant H2AX (gH2AX) and R-loop accumulation as measured by immunofluorescence (IF) with the S9.6 antibody (Figures S5A and S5B) .
Next, we examined the R-loop response following CPT treatment on the b-actin gene ( Figure 5A ). CPT triggered a reduction of R-loops over the prom and in1 regions, which correlated with transcriptional downregulation detected by Pol II ChIP (Figure S5C) . This is in line with previously reported effects of CPT on Pol II transcription (Khobta et al., 2006) . In contrast, CPT enhanced R-loop formation over in3, in5, and 5 0 pause regions ( Figure 5A ). This coincided with the induction of gH2AX (Figure S5D ). It is interesting that R-loops were most dramatically induced after 20 min, followed by a steady reduction, reaching the basal level at $240 min. These striking kinetics suggest that CPT-induced R-loops can be resolved efficiently by cellular factors. Therefore, we investigated the response of DHX9 to CPT-induced R-loop accumulation. ChIP analysis showed that despite a transcriptional downregulation ( Figure S5C ), DHX9 is enriched over the b-actin gene in response to CPT, and this binding is R-loop dependent because it is abolished by RNase H1 overexpression ( Figures 5B and 5C ). To test whether DHX9 is involved in the suppression of CPT-induced R-loops, we assessed R-loop levels in DHX9-depleted cells. In the absence of DHX9, CPT led to a dramatic increase in R-loops over in3, in5, and 5 0 pause b-actin regions ( Figure 5D ). RNase H treatment confirmed that CPT-induced DIP peaks were specific (Figure S5E) . Taken together, these results suggested that DHX9 is recruited to the b-actin gene to suppress CPT-induced R-loops.
DHX9 has been identified in MS screens for PARP1 and poly (ADP-ribos)ylation (PARylation) interactors (Gagné et al., 2012; Isabelle et al., 2010) . We identified PARP1 in the RNA/DNA hybrid interactome by MS and validated its interaction with RNA/DNA hybrids in vivo ( Figures 2F and 3C ). Furthermore, we observed an increase in the global level of R-loops in PARP1-depleted cells ( Figure 3I ). Next, we examined whether PARP1 is involved in R-loop-driven DNA damage, similar to DHX9. CoIP experiments showed that endogenous DHX9 and PARP1 proteins interact in both untreated and CPT-treated cells ( Figure 5E ). Similar to DHX9, PARP1 was recruited to the b-actin gene in response to CPT ( Figure 5F ). Moreover, the CPT-induced R-loop signal was increased over in5 and 3 0 end of the b-actin gene upon PARP inhibition with Olaparib (10 and 0.1 mM) or PARP1 depletion . However, PARP inhibition did not further increase the R-loop signal on the in5 of the b-actin gene in DHX9-depleted cells, suggesting that DHX9 and PARP1 act in the same pathway to suppress CPT-induced R-loops ( Figure S6D ). Next, we tested whether DHX9 and PARP1 are required for their reciprocal recruitment to chromatin in response to CPT. Depletion of PARP1 did not compromise DHX9 recruitment to the b-actin gene ( Figure S6E ). Similarly, PARP1 recruitment was not affected upon DHX9 loss ( Figure S6F ). These results suggest that DHX9 and PARP1 promote the suppression of CPT-induced R-loops independent of their reciprocal recruitment to chromatin.
DHX9 Prevents R-Loop-Dependent DNA Damage in
Response to CPT An excess of R-loops promotes DNA damage and genome instability (Aguilera and García-Muse, 2012; Skourti-Stathaki and Proudfoot, 2014; Sollier and Cimprich, 2015) . Therefore, we examined whether R-loop accumulation in DHX9-depleted cells caused a global increase in R-loop-dependent DNA damage by analyzing gH2AX signal by IF. In line with the increased accumulation of R-loops ( Figure 5D ), DHX9-depleted cells showed a significant increase in gH2AX signal following CPT treatment ( Figure 6A induction, which is consistent with co-transcriptional formation of R-loops ( Figures 6A and S7A) . Furthermore, overexpression of RNase H1 significantly reduced the CPT-induced gH2AX signal in DHX9-depleted cells ( Figure 6B ). Co-staining against RNase H1 showed that cells overexpressing RNase H1 exhibited low gH2AX levels, while non-expressing cells showed high gH2AX signal ( Figure S7B ). Therefore, our data demonstrate that DHX9 prevents R-loop-associated DNA damage in response to CPT.
R-Loop Helicases and Cancer
The role of DHX9 in R-loop-associated DNA damage pointed toward its potential involvement in human cancer because one of cancer hallmarks is widespread genomic instability. In addition to DHX9, other DEAD/H helicases were enriched in the RNA/DNA hybrid interactome ( Figure 7A ), suggesting a general role for these helicases in R-loop processes. In agreement with a possible role for these RNA/DNA hybrid-interacting helicases in cancer, analysis of the COSMIC cancer dataset (Forbes et al., 2015) revealed that these DEAD/H helicases are frequently genetically amplified in cancer, similar to known oncogenes SKP2 and MDM2 ( Figure 7B ). Moreover, most identified helicases, including DHX9 and DDX5, showed mRNA overexpression in a range of cancers, based on the ONCOMINE database (Rhodes et al., 2007) ( Figure 7C ). Therefore, R-loop-interacting helicases may play a role in oncogenesis or cancer development.
DISCUSSION
In this study, we established and validated a specific affinitybased MS approach with the S9.6 antibody to define a comprehensive RNA/DNA hybrid interactome in HeLa cells (Figures 1  and 2 ). The RNA/DNA hybrid interactome represents a unique functional subset of the total HeLa proteome enriched for dual DNA-and RNA-binding proteins and RNA-processing factors. It comprises several proteins with previously described functions in R-loop biology, such as SRSF1, Top1, and FACT (Aguilera and García-Muse, 2012; Skourti-Stathaki and Proudfoot, 2014) . The RNA/DNA hybrid interactome also reveals several new classes of in vivo RNA/DNA hybrid-binding proteins, including RNA-processing factors, helicases, histone modifiers, and DNA repair factors (Figure 2 ; Table S2 ), suggesting that these processes are linked to R-loops. It should be noted that some expected proteins, including SETX and RNase H1, were not identified by MS. This could be because of limited MS sensitivity for lowabundance proteins or their dynamic association with RNA/ DNA hybrids in vivo. We experimentally validated a number of new candidates from the RNA/DNA hybrid interactome and demonstrated their possible implication in R-loop biology (Figure 3) . Although future work is required to determine the specific function of these proteins in R-loop metabolism, these data highlight the value of the RNA/DNA hybrid interactome in understanding R-loop biology.
In this article, we specifically focused on R-loop-associated function of a top interactome candidate, helicase DHX9. Previous work demonstrated that DHX9 can resolve RNA/DNA hybrids in vitro (Chakraborty and Grosse, 2011) . We report here that DHX9 interacts with RNA/DNA hybrids in vivo and it promotes R-loop suppression and transcriptional termination (Figure 4) . Furthermore, DHX9 is important for maintaining genomic stability in response to CPT by preventing R-loop accumulation (Figures 5 and 6 ). However, it is not clear how DHX9 recognizes and suppresses physiological R-loops at transcription termination regions and CPT-induced R-loops.
DHX9 is involved in various aspects of RNA metabolism (Lee and Pelletier, 2016), and its depletion results in altered transcription (Chen et al., 2014) . This broad involvement in transcription underlies the global decrease of R-loop levels detected by slot blot and IF upon DHX9 depletion (Figure 3 ). The new characterized role of DHX9 in transcriptional termination accounts for the specific R-loop accumulation at the termination regions of b-actin and g-actin genes (Figure 4) . In this respect, DHX9 behaves similarly to SETX (Skourti-Stathaki et al., 2011) . DHX9 can regulate transcription either by binding directly to RNA (Liu et al., 2013) and gene promoters (Myö hä nen and Baylin, 2001) or by mechanisms dependent on its nucleoside-triphosphatase (NTPase)/helicase activity (Nakajima et al., 1997) and its ability to coordinate protein-protein interactions (Anderson et al., 1998) . Indeed, DHX9 interacts with a large number of proteins that function at the interface of transcription and DNA damage response, including RNA Pol II, CBP, BRCA1 (Anderson et al., 1998; Nakajima et al., 1997) , SMN (Pellizzoni et al., 2001 ), DDX5 (Hegele et al., 2012) , topoisomerase IIa (Zhou et al., 2003) , and DNA-PK (Mischo et al., 2005) . Therefore, DHX9 may be recruited to the promoters of transcribed genes by different mechanisms, and then, by interacting with Pol II, it can travel along the gene suppressing the arising R-loops.
Endogenous DHX9 is found in the same complexes as PARP1, another RNA/DNA hybrid interactor ( Figure 5 ), which is in line with data from MS screens for PARP1 and PARylation interactors (Gagné et al., 2012; Isabelle et al., 2010) . The loss of DHX9 and PARP1 independently results in increased R-loop accumulation following CPT treatment. An intriguing possibility is that DHX9 and PARP1 could be in the same pathway to suppress CPT-induced R-loops. PARP1 is not required for DHX9 recruitment to chromatin, but it may regulate DHX9 helicase activity in a similar way as it regulates the activity of the Werner syndrome helicase (von Kobbe et al., 2004) . Moreover, our data show that following CPT treatment, PARP1 and DHX9 both are recruited in the body and at the 3 0 end of the b-actin gene, 2014) and in other DNA repair pathways (Tallis et al., 2014) . Therefore, following CPT treatment, PARP1 also could be recruited to the b-actin gene because of its function in DNA repair, independent of R-loop induction. This may explain the lack of exact co-localization between DHX9, PARP1, and CPT-induced R-loop peaks over the b-actin gene. In addition to a potential model of cooperation between PARP1 and DHX9 in processing R-loops, different non-exclusive mechanisms could exist. First, PARP1 has many interactors that could process R-loops (Isabelle et al., 2010) . Second, PARylation itself triggers the recruitment of RNA-processing factors such as FUS, TAF15, EWSF1, and SAFA to DNA damage (Britton et al., 2014) . These factors are known R-loop suppressors (Aguilera and García-Muse, 2012; Skourti-Stathaki and Proudfoot, 2014). Finally, R-loop accumulation could be a consequence of impaired DNA damage repair. Indeed, R-loops have been described at DNA breaks (Britton et al., 2014; Cohen et al., 2018) . Our data suggest a potential role of PARP1 in controlling R-loop balance, but given the complexity of this scenario, further studies are required to understand the mechanistic details underlying PARP1 function in R-loop metabolism.
Recently, it has been demonstrated that increased global transcription in response to oncogenes or hormones is a characteristic of cancer (Kotsantis et al., 2016; Stork et al., 2016) . This transcriptional burst is accompanied by the accumulation of R-loops, which directly contributes to replication stress and genomic instability (Aguilera and García-Muse, 2012; SkourtiStathaki and Proudfoot, 2014; Sollier and Cimprich, 2015) . These findings suggest that an increased R-loop level could be a common feature of cancer cells. We found that multiple members of the DEAD/H helicase family, including DHX9, are strongly enriched in the RNA/DNA hybrid interactome and they are frequently deregulated in a range of cancers (Figure 7 ). These helicases may be required to support a higher transcriptional and RNA metabolic activity of cancer cells because of their role in transcription, RNA processing, and export. However, DHX9 and other DEAD/H helicases also may be upregulated in cancer to prevent R-loop accumulation or to promote the restart of replication forks stalled by the excess of R-loops. Future work will determine whether these helicases play a role in oncogenesis, tumor progression, or drug resistance by promoting R-loop processing.
In conclusion, our study provides the first proteomic characterization of factors interacting with RNA/DNA hybrids in vivo, offering a new perspective on cellular R-loop functions, including transcriptional termination and maintenance of genome stability ( Figure 7D) . Thus, the RNA/DNA hybrid interactome constitutes a powerful resource to study R-loop biology in health and disease.
EXPERIMENTAL PROCEDURES
Cell Culture, Transfections, and Drug Treatments HeLa and HEK293T cells were grown as described (Skourti-Stathaki et al., 2011) . Cells were treated with 5 mg/mL actinomycin D for 6 hr, 10 mM CPT for the indicated time, 100 mM DRB for 3 hr, 50 mM cordycepin for 4 hr, and 10 mM or 0.1 mM Olaparib for 1 hr. Cell transfections are described in Supplemental Experimental Procedures.
ChIP and DIP Analysis
ChIP with 2-5 mg of the indicated antibodies was carried out as described (Groh et al., 2014) . DIP analysis with the S9.6 antibody (Boguslawski et al., 1986) was described by Groh et al. (2014) and Skourti-Stathaki et al. (2011) . RNase H digestion with 1.5 U RNase H (M0297, NEB) per microgram genomic DNA for 2.5 hr at 37 C was carried out before IP. The amount of immunoprecipitated material at a particular gene region was calculated as the percentage of input after subtracting the background signal (no antibody control). Where stated, the values were normalized to the indicated probes.
RNA/DNA Hybrid IP Non-crosslinked HeLa cells were lysed in 85 mM KCl, 5 mM PIPES (pH 8.0), and 0.5% NP-40 for 10 min on ice. Pelleted nuclei were resuspended in RSB buffer (10 mM Tris-HCl pH 7.5, 200 mM NaCl, 2.5 mM MgCl2) with 0.2% sodium deoxycholate [NaDOC], 0.1% SDS, 0.05% sodium lauroyl sarcosinate [Na sarkosyl] and 0.5% Triton X-100, and extracts were sonicated for 10 min (Diagenode Bioruptor). Extracts were then diluted 1:4 in RSB with 0.5% Triton X-100 (RSB + T) and subjected to IP with the S9.6 antibody, bound to protein A dynabeads (Invitrogen), and preblocked with 0.5% BSA/PBS for 2 hr. CBP80 and IgG2a antibodies were used as control. RNase A (PureLink, Invitrogen) was added during IP at 0.1 ng RNase A per microgram genomic DNA. Beads were washed 4x with RSB + T; 2x with RSB; and eluted either in 2x LDS (Invitrogen), 100 mM DTT for 10 min at 70 C (for SDS-PAGE), or 1% SDS and 0.1 M NaHCO 3
for 30 min at room temperature (for RNA/DNA hybrid slot blot). Where indicated, nuclear extracts were treated with 1 U/mL benzonase (Sigma) for 30 min at 37 C before IP. Sequences and preparation of double- Table S1 provides the list of proteins that make up the RNA/DNA interactome.
Statistical Analysis
Unless otherwise stated, values represent the means ± SEMs based on at least three independent experiments. Asterisks indicate statistical significance (*p < 0.05; **p < 0.01; ***p < 0.001), based on unpaired, two-tailed Student's t test. Correlations were calculated using Pearson's correlation coefficient (r).
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA/DNA interactome reported in this paper is PRIDE: PXD002960 (http://www.ebi.ac.uk/pride/archive/login). Agarose gel analysis of DNA fragment sizes from RNA/DNA hybrid IP samples, sonicated for 5, 10 and 15 min. DNA size markers are shown to the left of the gel. B.
SUPPLEMENTAL INFORMATION
Agarose gel analysis of RNA trimming by RNase A during RNA/DNA hybrid IP. 5 µg of purified genomic DNA, prepared according to the RNA/DNA hybrid IP protocol, was treated with RNase A for 2h at 37°C. Control samples (Ctrl 1 and Ctrl 2) were not treated with RNase A. The migration of genomic DNA and ribosomal RNA (18S and 28S rRNA) is indicated on the right of the gel. C.
S9.6 antibody specifically recognises endogenous and synthetic RNA/DNA hybrids at a wide range of concentrations. Slot blot analysis with S9.6 antibody. Different amounts of endogenous and synthetic RNA/DNA hybrids were loaded on the slot blot. 300 ng of indicated synthetic single-stranded oligonucleotides were used as negative controls (right top panel). D.
Silver-stain of CBP80 IP with nucleic acid competitors added at 1.3 uM. E.
RNA/DNA hybrid slot blot after benzonase treatment. A. RNA/DNA hybrid IP is highly reproducible. The panel shows the correlation between log 2 enrichment RNA/DNA hybrid IP / Control IP of proteins quantified in three independent biological replicates of RNA/DNA hybrid IP by mass spectrometry. B. Volcano plot displaying mass spectrometry results of three biological replicates of RNA/DNA hybrid IP experiments, using normalised spectral indexes (SIN) quantification method, as implemented in the SINQ software (Trudgian et al., 2011) . Averaged log 2 ratios between RNA/DNA hybrid IP and control IP, carried out in the presence of 1.3 uM synthetic RNA/DNA hybrid, are plotted against their Benjamini-Hochberg corrected -log 10 pvalues calculated across all three biological replicates using a moderated t-test. Proteins (n=338) -+ + - (Thermo Fisher) 5'-GGACUCCAUCAGAUACUAU-3' WHSC1 siRNA (Thermo Fisher) 5'-AACGGCCAGAACAAGCUCUUA -3' SAFB2 siRNA (Thermo Fisher) 5'-GAGUCAGGAUCGCAAGUCA-3' DNA-PK siRNA (Thermo Fisher) 5'-GGGCGCUAAUCGUACUGAA-3' PARP1 siRNA (Thermo Fisher) 5'-GAAAGUGUGUUCAACUAAU-3' siRNA and plasmid transfections Transfection of plasmids and siRNAs was performed with Lipofectamine 2000 (Thermo Fisher Scientific) using the manufacturer's instructions. HeLa cells were transfected for 24 h and HEK293T cells for 48 h with pFlag (Sigma Aldrich, E7398), RNaseH1-Flag or RNaseH1-no tag plasmid (Groh et al., 2014) . RNA interference was performed with Lipofectamine 2000 (Thermo Fisher Scientific) using the manufacturer's instructions. DHX9 and SETX siRNAs were transfected as described (Andersen et al., 2013) .
